# Professor Robert Seamans is interviewed about Purdue Pharma's shift away from OxyContin

1 Faculty News June 24, 2018 ![Stamford Advocate 192 x 144](/sites/default/files/styles/246w/public/assets/images/stamfordadvocate192x144.jpg?itok=vvoCZKgc)>

Excerpt from the [Stamford Advocate](https://www.stamfordadvocate.com/business/article/Purdue-Pharma-sales-team-s-demise-signals-major-13017683.php) -- "Moving away from opioids is 'definitely a risk, but it seems like a risk worth taking,' said [Robert Seamans](http://www.stern.nyu.edu/faculty/bio/robert-seamans), an associate professor of management and organizations at New York University. 'To a certain extent, it seems like these types of sharp turns in strategy work better when private companies are making them. And since the CEO comes from the R&D side of the business, it sounds like they have the right person in place, now they have decided to pursue R&D instead of sales.'"

[Read more](https://www.stamfordadvocate.com/business/article/Purdue-Pharma-sales-team-s-demise-signals-major-13017683.php)